Smith & Nephew plc
) continues to focus on portfolio expansion as it rolled out its
new Modular Rail System (MRS) for external fixation and deformity
correction. The concept of MRS was developed by Dror Paley, MD,
of the Paley Advanced Limb Lengthening Institute at St. Mary's
Medical Center in West Palm Beach, FL.
Based on the body's ability to generate new bone tissue, MRS is
specifically designed to correct bone deformities, malunions,
non-unions and limb length discrepancies. The company's latest
system deploys a segmented, external rail and a series of
half-pins to hold together the several bone components until new
bone tissue grows and matures.
MRS is different from most of the other rail systems available
in the market as it can span a patient's joint. This enables the
patient to function normally while the device is in place.
CAREFUSION CORP (CFN): Free Stock Analysis
CONCEPTUS INC (CPTS): Free Stock Analysis
HANGER ORTHOPED (HGR): Free Stock Analysis
SMITH & NEPHEW (SNN): Free Stock Analysis
To read this article on Zacks.com click here.
The length of MRS can be adjusted according to patient's anatomy
because of its modular rail system. Moreover, the system can be
joined with other components from the company's TAYLOR SPATIAL
FRAME and ILIZAROV circular fixation device. Considering the
modular, multiplanar rail which enables length adjustments, the
system can be used for the hip, knee, ankle or elbow joints.
Recently, Smith & Nephew shifted its focus to its Advanced
Wound Management franchise, away from a clouded orthopedic space.
The introduction of MRS reflects a strategic measure to increase
investment in its extremities and limb restoration portfolio. We
believe that the company's innovative products should leverage
sales in a fast growing extremities market.
Despite pressure due to the looming macroeconomic concerns, Smith
& Nephew's investment in its extremity platform is likely to
result in sales expansion with increasing procedural uptake. We
expect the company to witness higher growth with the gradual
recovery of the economy.
The stock carries a Zacks Rank #3 (Hold). While we remain on the
sidelines for Smith & Nephew, other stocks in the medical
devices space such as
) warrant a look. These stocks carry a Zacks Rank #2 (Buy).